News

A Marquette University team is leading a new project that will combine balance and cardio training with the goal of improving the walking abilities of people with multiple sclerosis (MS). Led by Marquette biomedical engineering professor Brian Schmit, PhD, the project — which is supported by a $3.34 million…

An abnormally active metabolism in immune B-cells can trigger the release of pro-inflammatory signaling molecules that drive further inflammation in multiple sclerosis (MS), a study found. Selectively blocking certain metabolic processes with a Bruton’s tyrosine kinase (BTK) inhibitor normalized B-cell metabolism and shifted their signaling to an anti-inflammatory state.

People with multiple sclerosis (MS) who start treatment with a mild-to-moderate efficacy disease-modifying therapy (DMT) were more likely to switch to another DMT, an analysis of the German MS Registry finds. Starting a DMT between 2014 and 2017 was also a predictor of switching. Disease activity despite treatment…

Alternative splicing, a biological process that allows a single gene to code for multiple proteins, is extensively disrupted in immune cells isolated from untreated multiple sclerosis (MS) patients, and long-term treatment with interferon beta-based therapies largely corrects the defects, a study found. “Alternative splicing is a potential biomarker warning…

A small molecule called ESI1 stimulated the repair of the myelin sheath, the fatty coating on nerve fibers that is damaged in multiple sclerosis (MS), a study found. In an MS mouse model, this resulted in improved motor function and nerve cell communication, as well as reduced signs…

Alexander Gow, PhD, a professor at Wayne State University School of Medicine in Detroit, has been awarded a grant to study how stressed oligodendrocytes, the cells that produce myelin in the brain and spinal cord, could be at the origin of multiple sclerosis (MS). The three-year, $644,827 grant from…

The National Multiple Sclerosis Society has awarded Inflectis BioScience a grant valued at $649,601 to advance the preclinical development of IFB-048, the company’s experimental treatment to promote myelin repair in multiple sclerosis (MS). “This grant along with the support from the Society are a testimony…

Charles River Laboratories has joined up with FibroBiologics to manufacture the company’s spheroids for clinical trials in multiple sclerosis (MS) and several other conditions. The spheroids are groups of fibroblast cells arranged in a three-dimensional (3D) structure that more closely resemble how cells organize in living tissues.

Among immigrants to Canada, the risk of multiple sclerosis (MS) is higher for those who have spent a greater portion of their life in Canada, a new study reports. The study, “Proportion of Life Spent in Canada and the Incidence of Multiple Sclerosis in Permanent Immigrants,”…

Canada has one of the world’s highest rates of multiple sclerosis (MS) in the world, and this month residents are being urged to come together to raise awareness of and funds for people affected by the neurodegenerative disorder. May is Multiple Sclerosis Awareness Month in Canada, and…

A committee of the European Medicines Agency (EMA) is recommending the approval of a subcutaneous, or under-the-skin, formulation of Ocrevus (ocrelizumab) for people with multiple sclerosis (MS) in the European Union. The Committee for Medicinal Products for Human Use, known as CHMP, specifically recommended that this new formulation…

NKTR-0165, an antibody that targets the tumor necrosis factor receptor type 2 (TNFR2), will continue to be developed by Nektar Therapeutics as a candidate for treating multiple sclerosis (MS) and other autoimmune diseases. The experimental therapy was developed under a 2021 collaboration between Nektar and Biolojic…

A specialized imaging approach was able to detect signs of persistent inflammation in the brains of people with multiple sclerosis (MS) that aren’t readily captured by standard MRI scans. This so-called smoldering inflammation was also observed among those patients taking high-efficacy disease-modifying therapies (DMTs), where a higher degree…

A lower dose of the experimental oral therapy vidofludimus calcium (IMU-838) was not as effective as higher doses at reducing lesions in people with relapsing-remitting multiple sclerosis (RRMS), extended data from the therapy’s Phase 2 EMPhASIS trial show. “We found that doses of 30 mg and 45 mg,…

For people who develop multiple sclerosis (MS), the disease can exact a toll on their ability to work and on how much they earn in the private sector, according to a study by researchers in France, who said policies need to be enacted to replace lost income. “The effects…

A new machine learning model is able to predict the risk of converting from clinically isolated syndrome, or a first event of multiple sclerosis (MS)-like symptoms, to clinically definite disease, a study found. “Our study developed a machine-learning model that not only provides a numerical estimate of the…

There’s no evidence to suggest that multiple sclerosis (MS) directly causes most cancers, but having the condition may marginally increase the likelihood of developing cervical cancer, according to a new study from China. That study found “no causal relationship between MS and 15 types of cancers except cervical cancer,”…

People with multiple sclerosis (MS) who are being treated with Tysabri (natalizumab) tend to prefer receiving the medication as a subcutaneous (under-the-skin) injection rather than an intravenous (into-the-vein) infusion, according to new data from an observational study. “Based on current data, there is a trend toward patients’ preference…

Fully 70% of patients with nonactive secondary progressive multiple sclerosis (SPMS) who received foralumab nasal spray in an expanded access program (EAP) experienced a lessening in fatigue levels after six months of treatment. That’s according to early findings from the EAP — a program that enables patients with serious…

Researchers have identified a distinct profile of self-reactive antibodies that appear in the blood years before the first clinical signs of multiple sclerosis (MS), which they believe could be used to help diagnose the neurodegenerative disease. The antibodies were found in about 10% of people who developed MS and…

With this year’s fundraiser, the Multiple Sclerosis Association of America (MSAA) is marking its 10th annual Improving Lives Benefit — an event that shines a light on uplifting members of the multiple sclerosis (MS) community and outstanding corporate partners. The affair will take place on May 15 at…

A subcutaneous (under-the-skin) formulation of Ocrevus (ocrelizumab) helped most adults with multiple sclerosis (MS) remain free of clinical relapses and new or worsening brain lesions, according to one-year data from the Phase 3 OCARINA II study. Given twice a year as a 10-minute injection, this formulation of Ocrevus…

Viatris has launched a generic version of low-dose Copaxone (glatiramer acetate) in the Canadian market for the treatment of people with relapsing-remitting multiple sclerosis (RRMS) who retain the ability to walk. Called Glatiramer Acetate Injection 20 mg/mL, the product was approved in Canada as a generic of…

Two years of treatment with Briumvi (ublituximab) in clinical trials resulted in a confirmed reduction in disability for more than 1 in 10 people with early relapsing multiple sclerosis (MS) who had not received any prior treatment. That’s according to new data from the ULTIMATE Phase 3 trials,…

Ocrevus (ocrelizumab) continued to prevent disability progression among people with relapsing and progressive forms of multiple sclerosis (MS) over 10 years, according to clinical trial analyses. The most pronounced benefits were observed in patients who started on the therapy in the controlled part of the trials, compared with…

For people recently diagnosed with multiple sclerosis (MS), first-line treatment with Kesimpta (ofatumumab) was associated with a lower risk of disability progression over starting it after about 2.5 years of using Aubagio (teriflunomide). That’s according to six years of data spanning the ASCLEPIOS I (NCT02792218) and…

Long-term treatment with Clene Nanomedicine‘s experimental oral therapy CNM-Au8 led to signs of sustained improvements in nerve and myelin health for people with relapsing-remitting multiple sclerosis (RRMS) over three years, according to new data from the VISIONARY-MS clinical trial. The findings continue to support Clene’s plans to…

Ocrevus (ocrelizumab) had similar benefits in Black and Hispanic multiple sclerosis (MS) patients as earlier clinical trials with white patients did, one-year data from the CHIMES clinical trial indicates. About half of the CHIMES participants achieved no evidence of disease activity, or NEDA, which is defined as the…

Undergoing fertility treatment with assistive reproductive technologies does not increase the likelihood of having a relapse for women with multiple sclerosis (MS) who are taking a disease-modifying therapy (DMT), according to a new analysis. “The results are reassurance for women with MS who plan to undergo assistive reproductive…

High blood levels of the nerve damage biomarker neurofilament light chain (NfL) significantly increased the risk of people with clinically isolated syndrome (CIS) converting to definite multiple sclerosis (MS), according to an analysis of clinical trial data. CIS patients with higher NfL levels also made the transition earlier…